Jones Collombin Investment Counsel Inc lowered its stake in Pfizer Inc. (NYSE:PFE) by 5.8% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 246,915 shares of the biopharmaceutical company’s stock after selling 15,230 shares during the quarter. Pfizer comprises 2.9% of Jones Collombin Investment Counsel Inc’s portfolio, making the stock its 11th largest position. Jones Collombin Investment Counsel Inc’s holdings in Pfizer were worth $8,943,000 as of its most recent filing with the SEC.

Several other hedge funds also recently bought and sold shares of PFE. Mckinley Capital Management LLC Delaware acquired a new stake in Pfizer during the 2nd quarter valued at approximately $103,000. Herndon Capital Management LLC acquired a new stake in Pfizer during the 2nd quarter valued at approximately $120,000. Americafirst Capital Management LLC acquired a new stake in Pfizer during the 3rd quarter valued at approximately $127,000. Private Vista LLC grew its stake in Pfizer by 2,277.3% during the 2nd quarter. Private Vista LLC now owns 199,317 shares of the biopharmaceutical company’s stock valued at $133,000 after purchasing an additional 190,933 shares in the last quarter. Finally, Lipe & Dalton grew its stake in Pfizer by 6.9% during the 2nd quarter. Lipe & Dalton now owns 4,626 shares of the biopharmaceutical company’s stock valued at $155,000 after purchasing an additional 300 shares in the last quarter. Institutional investors and hedge funds own 71.16% of the company’s stock.

How to Become a New Pot Stock Millionaire

A number of brokerages have weighed in on PFE. BMO Capital Markets set a $43.00 price objective on Pfizer and gave the company a “buy” rating in a research note on Tuesday, March 6th. Jefferies Group set a $39.00 price objective on Pfizer and gave the company a “hold” rating in a research note on Monday, February 26th. Barclays raised their price objective on Pfizer from $38.00 to $41.00 and gave the company an “overweight” rating in a research note on Wednesday, January 31st. Credit Suisse Group raised their price objective on Pfizer from $37.00 to $39.00 and gave the company a “neutral” rating in a research note on Wednesday, January 31st. Finally, Leerink Swann raised their price objective on Pfizer from $35.00 to $38.00 and gave the company a “market perform” rating in a research note on Wednesday, January 31st. Two investment analysts have rated the stock with a sell rating, ten have assigned a hold rating and eleven have issued a buy rating to the company’s stock. Pfizer has a consensus rating of “Hold” and an average target price of $39.40.

In related news, EVP Sally Susman sold 33,368 shares of the firm’s stock in a transaction that occurred on Tuesday, February 27th. The stock was sold at an average price of $37.03, for a total value of $1,235,617.04. Following the sale, the executive vice president now owns 191,505 shares of the company’s stock, valued at approximately $7,091,430.15. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Kirsten Lund-Jurgensen sold 9,510 shares of the firm’s stock in a transaction that occurred on Monday, February 26th. The stock was sold at an average price of $37.19, for a total value of $353,676.90. Following the completion of the sale, the insider now directly owns 36,959 shares in the company, valued at approximately $1,374,505.21. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 248,037 shares of company stock worth $9,064,785. 0.06% of the stock is currently owned by company insiders.

Pfizer Inc. (NYSE PFE) opened at $35.60 on Friday. The company has a current ratio of 1.35, a quick ratio of 1.10 and a debt-to-equity ratio of 0.47. Pfizer Inc. has a 1-year low of $31.67 and a 1-year high of $39.43. The company has a market capitalization of $215,910.41, a P/E ratio of 13.69, a price-to-earnings-growth ratio of 1.82 and a beta of 0.91.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.62 EPS for the quarter, topping analysts’ consensus estimates of $0.56 by $0.06. Pfizer had a return on equity of 25.21% and a net margin of 40.55%. The company had revenue of $13.70 billion for the quarter, compared to the consensus estimate of $13.67 billion. During the same quarter last year, the business posted $0.47 EPS. Pfizer’s quarterly revenue was up .6% compared to the same quarter last year. sell-side analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer announced that its Board of Directors has initiated a stock repurchase program on Monday, December 18th that authorizes the company to repurchase $10.00 billion in outstanding shares. This repurchase authorization authorizes the biopharmaceutical company to reacquire shares of its stock through open market purchases. Shares repurchase programs are generally an indication that the company’s management believes its stock is undervalued.

ILLEGAL ACTIVITY WARNING: “Jones Collombin Investment Counsel Inc Sells 15,230 Shares of Pfizer Inc. (PFE)” was first published by Watch List News and is owned by of Watch List News. If you are reading this article on another publication, it was stolen and republished in violation of United States and international copyright & trademark legislation. The legal version of this article can be accessed at https://www.watchlistnews.com/jones-collombin-investment-counsel-inc-sells-15230-shares-of-pfizer-inc-pfe/1959825.html.

Pfizer Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.